Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines

This article was originally published in The Gray Sheet

Executive Summary

The U.S. Preventive Services Task Force finds the evidence inconclusive for employing human papillomavirus testing as part of cervical cancer screening for women over 30, and it explicitly recommends against HPV testing in younger women.

You may also be interested in...



FDA Panel Supports Roche HPV Assay To Replace Pap As Primary Cervical Cancer Screen

The Microbiology Devices Panel provided unanimous support Roche’s submission to upgrade labeling for it cobas HPV test as a first-line, primary screen for cervical cancer.

New Products In Brief

Abbott earns approval in Japan for Xience Xpedition everolimus-eluting stent. Zimmer will distribute SpineCraft’s APEX system. More new product news.

News In Brief

Sanofi picks up Pluromed. Arriva Medical buys AmMed Direct. Sanuwave gives PMA status update. More news briefs.

Related Content

Topics

UsernamePublicRestriction

Register

MT030658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel